Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Rating) – Investment analysts at HC Wainwright issued their Q3 2023 EPS estimates for shares of Black Diamond Therapeutics in a research note issued to investors on Tuesday, March 14th. HC Wainwright analyst R. Burns expects that the company will earn ($0.65) per share for the quarter. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.76) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q4 2023 earnings at ($0.67) EPS and FY2023 earnings at ($2.56) EPS.
Black Diamond Therapeutics Price Performance
BDTX opened at $1.67 on Thursday. The company has a 50 day simple moving average of $2.44 and a two-hundred day simple moving average of $2.16. The firm has a market cap of $60.92 million, a P/E ratio of -0.66 and a beta of 1.86. Black Diamond Therapeutics has a 1-year low of $1.18 and a 1-year high of $4.08.
Institutional Investors Weigh In On Black Diamond Therapeutics
Black Diamond Therapeutics Company Profile
Black Diamond Therapeutics, Inc, a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations.
- Get a free copy of the StockNews.com research report on Black Diamond Therapeutics (BDTX)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.